» Articles » PMID: 19103312

The Modification of Alpha-synuclein by Dicarbonyl Compounds Inhibits Its Fibril-forming Process

Overview
Specialties Biochemistry
Biophysics
Date 2008 Dec 24
PMID 19103312
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative modification of alpha-synuclein (alphaSyn) was reported to have significant effects on its amyloidogenic properties. Dicarbonyl compounds are metabolites accumulated by various oxidative processes in the intracellular environment. In this study, two dicarbonyl compounds, methylglyoxal (MGO) and glyoxal (GO), were investigated for their effects on the structural and fibril-forming properties of alphaSyn. Both compounds were found to induce the oligomerization of alphaSyn. By adding substoichiometric amounts of alphaSyn modified by MGO or GO, the fibrillization of alphaSyn was substantially inhibited. The heterogeneously-modified alphaSyns were separated into three fractions: monomers, oligomers, and high molecular mass oligomers. When each modified alphaSyn species was used to seed fibril formation, protein fibrillization was significantly suppressed. Temperature scanning and interactions with liposomes revealed that both MGO- and GO-modified monomers were not as susceptible as the unmodified alphaSyn to conformational changes into partially folded intermediates and alpha-helixes. Our observations suggest that dicarbonyl modification of alphaSyn reduces conformational flexibility of the protein, thereby contributing to a reduction in the ability of alphaSyn to form fibrils, and the modified protein inhibits the fibrillization of the unmodified alphaSyn.

Citing Articles

Non-enzymatic posttranslational protein modifications in protein aggregation and neurodegenerative diseases.

Baldensperger T, Preissler M, Becker C RSC Chem Biol. 2024; 6(2):129-149.

PMID: 39722676 PMC: 11667106. DOI: 10.1039/d4cb00221k.


Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.


Diabetes and Parkinson's Disease: Understanding Shared Molecular Mechanisms.

Konig A, Outeiro T J Parkinsons Dis. 2024; 14(5):917-924.

PMID: 38995799 PMC: 11307096. DOI: 10.3233/JPD-230104.


Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics.

Abioye A, Akintade D, Mitchell J, Olorode S, Adejare A Pharmaceutics. 2024; 16(5).

PMID: 38794271 PMC: 11124533. DOI: 10.3390/pharmaceutics16050609.


An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition.

Uceda A, Marino L, Casasnovas R, Adrover M Biophys Rev. 2024; 16(2):189-218.

PMID: 38737201 PMC: 11078917. DOI: 10.1007/s12551-024-01188-4.